CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
Clinical Trials
The Phase 3 VENTURA research study, which was assessing aticaprant as an adjunctive treatment for major depressive disorder (aMDD), has been discontinued by Johnson & Johnson because of its lack of effectiveness in the target patient population. No new safety signals were found, and the results verified that aticaprant is […]
The BEACON-IPF Phase 2b trial, which was assessing bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), has been discontinued by Pliant Therapeutics, Inc. after a predetermined data review and recommendation by the independent Data Safety Monitoring Board (DSMB) of the trial and a secondary review and recommendation by an external […]
The European Commission is currently taking final action on the application for the use of Jaypirca in patients with relapsed or refractory CLL who have received prior treatment with a BTK inhibitor as a result of this favorable view.
American pharma giant Merck’s application for KEYTRUDA® (pembrolizumab) receives US FDA’s priority review acceptance. Acceptance based on results from the KEYNOTE-689 trial. This is the first Phase 3 study to show a notable increase in event-free survival in the early stages of head and neck squamous cell carcinoma when using […]
Researchers at St. Jude Children’s Research Hospital report findings from a novel and promising treatment for the uncommon neurological disease.
Surgery to remove the tumor is the standard of care for individuals with stage III or IV clear cell renal cell carcinoma.
In preclinical models tested in mice, a possible novel targeted therapy for children brain cancer has been found to be successful in infiltrating and destroying tumor cells
Data from this 28-country multi-institutional effort helped the Food and Drug Administration (FDA) approve this combination more quickly in December 2024, giving patients with BRAF V600E-mutant mCRC a new and effective first-line treatment choice.
The huntingtin gene’s three DNA blocks (C, A, and G) repeatedly expanding are the source of the illness.
